News | July 28, 2008

New Guidelines Suggest Early Intervention for Certain Blood Clots in DVT

July 29, 2008 - The American College of Chest Physicians (ACCP) recently published new evidence-based clinical guidelines for physicians that for the first time suggest the use of pharmacomechanical thrombolysis for acute iliofemoral deep vein thrombosis (DVT) in conjunction with anticoagulation drug therapy.

The new guidelines appear in the July supplement to the CHEST journal.

“This is a major change in the recommendations for the care of these patients with extensive DVT, and represents a major advance in treatment. Adopting an initial strategy of thrombus removal will improve the quality of life of these patients and potentially avoid recurrent DVT in the future,” said Anthony J. Comerota, M.D., FACS, FACC, director of the Jobst Vascular Center and adjunct professor of surgery, University of Michigan.

“The recommendation to treat certain cases of acute DVT with pharmacomechanical thrombolysis adds an important tool to help treat the acute problem as well as to minimize the long-term disability of post-thrombotic syndrome (PTS) in patients," added Katharine L. Krol, M.D., director, vascular interventional radiology, CorVasc MDs, Indianapolis, IN and recent past president of the Society of Interventional Radiology (SIR).

The new venous thromboembolic (VTE) disease guidelines represent an evolution from the previous ACCP standard which recommended the use of anticoagulation drug therapy alone for the treatment of DVT. For complete information on the new ACCP VTE Guidelines, visit www.TheNewGuidelines.org.

While anticoagulation alone mitigates the risk of clot propagation and pulmonary embolism, it often fails to clear the blockage. This residual thrombus can lead to venous hypertension, valvular insufficiency, skin ulcerations and post-thrombotic syndrome.

The new guidelines suggesting the use of pharmacomechanical thrombolysis establishes a new standard, which gives a boost to pharmaceutical companies producing these drugs.

"The publication of the new 2008 ACCP guidelines suggesting the use of pharmacomechanical thrombolysis clearly establishes a new standard for thrombolytic therapy,” said Scott Cramer, president and CEO of Bacchus Vascular Inc., maker of the Trellis Peripheral Infusion System.

Isolated pharmacomechanical thrombolysis using the Trellis to deliver thrombolytic directly into a desired treatment segment has reportedly proven to be a rapid, effective and safe method of treating patients with acute DVT. The Trellis device is said to be the only DVT treatment system that isolates the thrombus and targets the thrombolytic treatment.

For more information: www.bacchusvascular.com, www.TheNewGuidelines.org

Related Content

Illustration of the EkoSonic catheter aiding drug-dispersion in a DVT clot. Catheter directed thrombolysis of deep vein thrombosis.

Illustration of the EkoSonic catheter aiding drug-dispersion in a DVT clot.

Feature | Deep Vein Thrombosis (DVT) | February 16, 2018 | Sanjay Pandya, M.D.
There are few downsides to using tibial venous access to treat...
ACCESS PTS Study Demonstrates Efficacy of EKOS Therapy for Post-Thrombotic Syndrome
News | Deep Vein Thrombosis (DVT) | July 07, 2017
BTG plc recently highlighted the results of the ACCESS PTS trial, presented at the Society for Vascular Medicine 28th...
NICE, U.K., edoxaban, Lixiana, VTE, venous thromboembolism, deep vein thrombosis, pulmonary embolism
News | Deep Vein Thrombosis (DVT) | August 12, 2015
The National Institute for Health and Care Excellence (NICE) has recommended a new treatment to help patients suffering...
Overlay Init